NYSEAMERICAN:ISR - Isoray Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.33
  • Forecasted Upside: -40.48 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.24
▼ -0.17 (-7.05%)
1 month | 3 months | 12 months
Get New Isoray Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ISR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ISR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$1.33
▼ -40.48% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Isoray in the last 3 months. The average price target is $1.33, with a high forecast of $1.75 and a low forecast of $1.00. The average price target represents a -40.48% upside from the last price of $2.24.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Isoray. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/1/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
12/16/2020OppenheimerInitiated CoverageOutperform$1.00
i
12/15/2020OppenheimerInitiated CoverageOutperform$1.00
i
11/12/2020HC WainwrightReiterated RatingBuy$1.25
i
10/20/2020Dawson JamesDowngradeBuy ➝ Neutral
i
Rating by J. Kolbert at Dawson James
5/15/2020Ascendiant Capital MarketsBoost Price TargetBuy$1.40 ➝ $1.75
i
2/12/2020HC WainwrightReiterated RatingBuy$0.70 ➝ $1.25
i
Rating by S. Ramakanth at HC Wainwright
7/1/2019Dawson JamesInitiated CoverageBuy
i
Rating by Jason Kolbert at Dawson James
5/13/2019HC WainwrightReiterated RatingBuy$0.70
i
Rating by Swayampakula Ramakanth at HC Wainwright
2/14/2019HC WainwrightSet Price TargetBuy$1.00
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/28/2019HC WainwrightReiterated RatingBuy
i
Rating by S. Ramakanth at HC Wainwright
11/13/2018HC WainwrightSet Price TargetHold$1.00
i
Rating by Jason Kolbert at HC Wainwright
11/9/2018Maxim GroupDowngradeBuy ➝ Hold
i
9/26/2018HC WainwrightSet Price TargetHold$1.00
i
Rating by J. Kolbert at HC Wainwright
9/26/2018Maxim GroupReiterated RatingBuy$2.00
i
Rating by Jason McCarthy at Maxim Group
8/20/2018HC WainwrightReiterated RatingNeutral
i
Rating by J. Kolbert at HC Wainwright
8/20/2018HC WainwrightInitiated CoverageNeutral$1.00
i
Rating by Jason Kolbert at HC Wainwright
5/4/2018Maxim GroupSet Price TargetBuy$2.00
i
Rating by Jason McCarthy at Maxim Group
4/2/2018Ascendiant Capital MarketsInitiated CoverageBuy$1.00
i
2/14/2018Maxim GroupSet Price TargetBuy ➝ Buy$3.00 ➝ $2.00
i
Rating by Jason Kolbert at Maxim Group
2/8/2018Maxim GroupSet Price TargetBuy$3.00 ➝ $2.00
i
Rating by Jason Kolbert at Maxim Group
1/24/2018Maxim GroupSet Price TargetBuy$3.00
i
Rating by Jason Kolbert at Maxim Group
11/15/2017Maxim GroupSet Price TargetBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
9/28/2017Maxim GroupReiterated RatingBuy$3.00
i
7/6/2017Maxim GroupSet Price TargetBuy$3.00
i
5/11/2017Maxim GroupSet Price TargetBuy$3.00
i
5/13/2016Maxim GroupReiterated RatingBuy$3.00
i
Rating by Jason Kolbert at Maxim Group
2/10/2016Maxim GroupReiterated RatingBuy
i
Rating by Jason Kolbert at Maxim Group
(Data available from 1/22/2016 forward)
Isoray logo
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Read More

Today's Range

Now: $2.24
$2.16
$2.37

50 Day Range

MA: $0.45
$0.41
$0.54

52 Week Range

Now: $2.24
$0.35
$2.81

Volume

7,427,941 shs

Average Volume

39,869,016 shs

Market Capitalization

$195.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Isoray?

The following Wall Street analysts have issued stock ratings on Isoray in the last twelve months: Ascendiant Capital Markets, Dawson James, HC Wainwright, Oppenheimer Holdings Inc., and Zacks Investment Research.

What is the current price target for Isoray?

3 Wall Street analysts have set twelve-month price targets for Isoray in the last year. Their average twelve-month price target is $1.33, suggesting a possible downside of 40.5%. Ascendiant Capital Markets has the highest price target set, predicting ISR will reach $1.75 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $1.00 for Isoray in the next year.

What is the current consensus analyst rating for Isoray?

Isoray currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ISR will outperform the market and that investors should add to their positions of Isoray.

What other companies compete with Isoray?

How do I contact Isoray's investor relations team?

Isoray's physical mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company's listed phone number is (509) 375-1202 and its investor relations email address is [email protected] The official website for Isoray is isoray.com.